GDTC
CytoMed Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$0.85
−3.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 720.1K | 319.2K | 69.5K | 509.1K | 365.6K |
| Cost of Revenue | 1.3M | 1.2M | 17.1K | 3.7K | 109.0K |
| Gross Profit | (593.4K) | (886.6K) | 52.4K | 505.4K | (109.0K) |
| Operating Expenses | |||||
| R&D Expense | 3.2M | 2.2M | 1.9M | 1.6M | 1.5M |
| SG&A Expense | 1.8M | 1.4M | 1.3M | 490.5K | 596.5K |
| General & Admin Expense | 453.7K | — | 1.2M | 457.1K | 596.5K |
| Selling & Marketing Expense | 33.0K | — | 23.8K | 33.4K | — |
| Other Expenses | 9.2K | 9.3K | 7.7K | — | 55.5K |
| Total Operating Expenses | 5.0M | 3.6M | 3.2M | 2.1M | 2.2M |
| Cost and Expenses | 6.3M | 4.8M | 3.2M | 2.1M | 2.3M |
| Operating Income (EBIT) | (5.6M) | (4.5M) | (3.1M) | (1.6M) | (2.3M) |
| Non-Operating | |||||
| Interest Income | 47.6K | 121.9K | 317.7K | 281.5K | 2.0K |
| Interest Expense | 15.6K | 20.6K | 20.3K | 50.5K | 122.1K |
| Net Interest Income | 31.6K | 101.3K | 297.4K | 231.0K | (120.1K) |
| Other Non-Op Income/Expense | 271.0K | 587.3K | 553.9K | (2.6M) | (770.9K) |
| Non-Operating Income (excl Interest) | 776.4K | — | (1.0M) | (243.0K) | 1.1M |
| EBT (Pre-Tax Income) | (5.3M) | (3.9M) | (2.6M) | (4.1M) | (3.1M) |
| Income Tax Expense | — | — | (54.7K) | 653.00 | 1.6K |
| Bottom Line | |||||
| Net Income | (5.3M) | (3.9M) | (2.5M) | (4.1M) | (3.1M) |
| Earnings from Cont. Ops | (5.3M) | (3.9M) | (2.5M) | (4.1M) | (3.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.3M) | (3.9M) | (2.5M) | (4.1M) | (3.1M) |
| Per Share | |||||
| Basic EPS | ($0.44) | ($0.33) | ($0.22) | ($0.38) | ($0.40) |
| Diluted EPS | ($0.44) | ($0.33) | ($0.22) | ($0.38) | ($0.40) |
| Revenue Per Share | $0.06 | $0.03 | $0.01 | $0.05 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 11.9M | 11.6M | 11.5M | 10.6M | 7.9M |
| Diluted Shares Outstanding | 11.9M | 11.6M | 11.5M | 10.6M | 7.9M |
| Profitability Metrics | |||||
| EBITDA | (5.9M) | (4.1M) | (1.8M) | (3.6M) | (1.9M) |
| D&A | 503.4K | 401.6K | 335.4K | 381.1K | 392.9K |
| EBIT | (6.4M) | (4.5M) | (2.1M) | (4.0M) | (2.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026